ML323 | CAS#1572414-83-5 | USP1-UAF1 inhibitor

MedKoo Cat#: 406534 | Name: ML-323

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML323 is a selective and highly potent USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. ML323 inhibits the USP1-UAF1 deubiquitinase complex with excellent selectivity against human DUBs, deSUMOylase, deneddylase and unrelated proteases. ML323 potentiates cisplatin cytotoxicity in non-small cell lung cancer and osteosarcoma cells. USP1-UAF1 is a key regulator of the DNA damage response and a target for overcoming resistance to the platinum-based anticancer drugs.

Chemical Structure

ML-323

CAS#1572414-83-5

Theoretical Analysis

MedKoo Cat#: 406534

Name: ML-323

CAS#: 1572414-83-5

Chemical Formula: C23H24N6

Exact Mass: 384.2062

Molecular Weight: 384.48

Elemental Analysis: C, 71.85; H, 6.29; N, 21.86

Price and Availability

Size	Price	Availability
25mg	USD 90.00	Ready to ship
50mg	USD 150.00	Ready to ship
100mg	USD 250.00	Ready to ship
200mg	USD 450.00	Ready to ship
500mg	USD 950.00	Ready to ship
1g	USD 1,750.00	2 weeks
2g	USD 3,250.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ML323; ML 323; ML-323.

IUPAC/Chemical Name

N-(4-(1H-1,2,3-triazol-1-yl)benzyl)-2-(2-isopropylphenyl)-5-methylpyrimidin-4-amine

InChi Key

VUIRVWPJNKZOSS-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H24N6/c1-16(2)20-6-4-5-7-21(20)23-24-14-17(3)22(27-23)25-15-18-8-10-19(11-9-18)29-13-12-26-28-29/h4-14,16H,15H2,1-3H3,(H,24,25,27)

SMILES Code

CC1=CN=C(C2=CC=CC=C2C(C)C)N=C1NCC3=CC=C(N4N=NC=C4)C=C3

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#BBC40825

QC Data

View QC data: current batch, Lot#BBC40825

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

ML-323 is a reversible, potent USP1-UAF1 inhibitor with IC50 of 76 nM in a Ub-Rho assay.

In vitro activity:

Analysis of cells by immunofluorescence method and confocal microscopy showed that the ML323 inhibitor affects the localization of the USP1 protein (Fig. 3). Despite that USP1 protein is a nuclear protein, after 1.5 h incubation with ML323, this study found not only nuclear but also cytoplasmic localization in some cells. By the third hour of incubation with ML323 protein USP1 was detected mainly in the cytoplasm, and in some cells, the protein was not detected at all. In this case, the РCC decreased from 0.63 to 0.23 as compared to the control. The MOC indices also decreased, both MOC M1 (fraction of USP1 overlapping Bcr-Abl) and MOC M2 indicating the almost complete absence of overlap of localization signals of Bсr-Abl oncoprotein with USP1 protein. After 24 h of incubation with ML323 only cytoplasmic localization of USP1 protein remains. Thus, the action of the ML323 inhibitor alters the localization of USP1 protein and significantly reduces the level of colocalization with Bcr-Abl oncoprotein. Reference: Exp Oncol. 2020 Jun;42(2):109-114. https://pubmed.ncbi.nlm.nih.gov/32602291/

In vivo activity:

ML323 treatment inhibited VSV-induced IFN-β production in peritoneal lavage (Fig. 5 I) and suppressed TBK1 protein expression in peritoneal exudate cells (Fig. 5 J). Furthermore, VSV infection induced IFN-β secretion was much less in sera of ML323-treated mice than in that of control mice (Fig. 5 K). Accordingly, IFN-β mRNA expression in the liver, lung, and spleen of ML323-treated mice was lower than that in controls (Fig. 5 L). In accordance with reduced IFN-β expression, VSV replication in the liver, lung, and spleen of ML323-treated mice was higher than that in controls (Fig. 5 M). Severe infiltration of immune cells was observed in the lungs of ML323-treated mice, compared with that of control mice after VSV infection (Fig. 5 N). Reference: J Exp Med. 2017 Dec 4; 214(12): 3553–3563. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716033/

	Solvent	mg/mL	mM
Solubility
	DMSO	44.6	116.03
	DMF	20.0	52.02
	Ethanol	32.2	83.62
	Ethanol:PBS (pH 7.2) (1:6)	0.1	0.36

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 384.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Antonenko SV, Telegeev GD. Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells. Exp Oncol. 2020 Jun;42(2):109-114. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14533. PMID: 32602291. 2. Kim JY, Choung PH. USP1 inhibitor ML323 enhances osteogenic potential of human dental pulp stem cells. Biochem Biophys Res Commun. 2020 Sep 17;530(2):418-424. doi: 10.1016/j.bbrc.2020.05.095. Epub 2020 Jun 14. PMID: 32546349. 3. Yu Z, Song H, Jia M, Zhang J, Wang W, Li Q, Zhang L, Zhao W. USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses. J Exp Med. 2017 Dec 4;214(12):3553-3563. doi: 10.1084/jem.20170180. Epub 2017 Nov 14. PMID: 29138248; PMCID: PMC5716033.

In vitro protocol:

In vivo protocol:

1. Yu Z, Song H, Jia M, Zhang J, Wang W, Li Q, Zhang L, Zhao W. USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses. J Exp Med. 2017 Dec 4;214(12):3553-3563. doi: 10.1084/jem.20170180. Epub 2017 Nov 14. PMID: 29138248; PMCID: PMC5716033.

1: Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil MA, You C, Zhang Q, Chen J, Ott CA, Sun H, Luci DK, Yuan B, Simeonov A, Jadhav A, Xiao H, Wang Y, Maloney DJ, Zhuang Z. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat Chem Biol. 2014 Apr;10(4):298-304. doi: 10.1038/nchembio.1455. Epub 2014 Feb 16. PubMed PMID: 24531842.